Please ensure Javascript is enabled for purposes of website accessibility

Why Amarin Stock Is Crashing Today

By Keith Speights - Mar 31, 2020 at 10:18AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech received disastrous news from a U.S. District Court ruling.

What happened

Amarin (AMRN 1.21%) shares were crashing on Tuesday, plunging 69.8% lower as of 9:55 a.m. The steep decline came after the U.S. District Court for the District of Nevada ruled in favor of generic-drug companies and invalidated Amarin's patent for Vascepa, which is approved by the FDA for treating high triglyceride levels and reducing cardiovascular risk. 

So what

Vascepa is Amarin's only approved drug. The entrance of generic rivals on the market would be a huge blow to the company, which only recently began promoting Vascepa as a treatment for reducing cardiovascular risk.

Man looking at red line chart crashing through the floor

Image source: Getty Images.

The court ruling applies only to the U.S. and not to Amarin's international patents for Vascepa. However, the U.S. is the most lucrative market. The presence of generic competition in the country would significantly reduce Amarin's growth prospects.

Amarin's efforts to market Vascepa have already taken a hit this year because of the coronavirus pandemic. The company announced on March 15 that it was suspending personal visits to physicians for its sales team for two weeks. Several other drugmakers have taken similar actions. 

However, this suspension of face-to-face interactions is only temporary. The patent invalidation for Vascepa, if it stands, will affect Amarin permanently.

Now what

Amarin released a statement that said the company "strongly disagrees with the ruling and will vigorously pursue all available remedies." Those remedies include an appeal of the court's decision. Expect Amarin to also file a preliminary injunction if the FDA approves abbreviated new drug applications (ANDAs) for generic rivals. Thus far, no ANDA has been approved for Vascepa.

The situation for Amarin underscores the enormous risks for small drugmakers with all their eggs in one basket. It's possible that Amarin could prevail in its challenge to the U.S. District Court ruling. In the meantime, though, the biotech stock isn't likely to rebound very much.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
AMRN
$1.67 (1.21%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.